ストックスクリーナーアプリを入手
3.08
2.33%
0.07
前日終値:
$3.01
開ける：
$3.05
24時間の取引高:
2.08M
Relative Volume:
1.60
時価総額：
$187.43M
収益：
$5.03M
当期純損益:
$-185.41M
株価収益率:
-0.9968
EPS:
-3.09
ネットキャッシュフロー:
$-139.79M
1週間 パフォーマンス:
+1.32%
1か月 パフォーマンス:
-72.18%
6か月 パフォーマンス:
-77.03%
1年 パフォーマンス:
-80.57%
1日の値動き範囲:
$2.995
$3.13
1週間の範囲:
$2.92
$3.22
52週間の値動き範囲:
$2.43
$18.00
Pliant Therapeutics Inc Stock (PLRX) Company Profile
名前
Pliant Therapeutics Inc
セクター
電話
650-481-6770
住所
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
PLRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
3.08 | 187.43M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-10 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-02-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-02-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-02-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-05-18 | 開始されました | Canaccord Genuity | Buy |
| 2023-04-13 | 開始されました | Robert W. Baird | Outperform |
| 2022-12-14 | 開始されました | Stifel | Buy |
| 2022-12-07 | 開始されました | JP Morgan | Overweight |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2022-07-20 | 開始されました | SVB Leerink | Outperform |
| 2022-05-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 開始されました | Oppenheimer | Outperform |
| 2021-11-24 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-03 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-20 | 開始されました | BTIG Research | Buy |
| 2021-04-05 | 開始されました | Citigroup | Buy |
| 2020-06-29 | 開始されました | Citigroup | Buy |
| 2020-06-29 | 開始されました | Cowen | Outperform |
| 2020-06-29 | 開始されました | Needham | Buy |
| 2020-06-29 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Pliant Therapeutics Inc (PLRX) 最新ニュース
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Connect - Markets Insider
Pliant Therapeutics (PLRX) to Release Quarterly Earnings on Tuesday - MarketBeat
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Stockholders to Inquire about Securities Investigation - Markets Insider
Pliant Therapeutics Inc (PLRX): Major Improvements, Worth A Look - Stocks Register
Wells Fargo downgrades Pliant Therapeutics Inc (PLRX) stock to an Equal weight - Knox Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Investors to Learn More About the Investigation - Markets Insider
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc.PLRX - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Investors to Inquire about Securities Investigation - Markets Insider
Pliant Therapeutics chief business officer Hull sells $178,500 in stock - MSN
Pliant Therapeutics' chief medical officer sells $206,973 in stock - MSN
Pliant Therapeutics general counsel Mike Ouimette sells $261,100 in stock - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Reach Out - Markets Insider
What is HC Wainwright's Forecast for PLRX FY2029 Earnings? - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Price Target Lowered to $10.00 at Needham & Company LLC - MarketBeat
Pliant Therapeutics' (PLRX) Market Perform Rating Reiterated at Oppenheimer - MarketBeat
Pliant Therapeutics Initiates Outside Expert Panel to Review BEACON-IPF Trial Data - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Given Hold Rating at Canaccord Genuity Group - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Stockholders to Reach Out - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Stockholders to Connect - ACCESS Newswire
Pliant Therapeutics' chief human resource officer sells $41,892 in stock - MSN
Pliant Thera lines up experts to review BEACON-IPF Phase IIb/III trial - The Pharma Letter
Pliant Therapeutics stock hits 52-week low at $2.52 - MSN
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Downgraded to Sector Perform Rating by Royal Bank of Canada - MarketBeat
Stifel maintains Pliant Therapeutics stock buy rating amid study pause By Investing.com - Investing.com Canada
Sector Update: Health Care Stocks Mixed Thursday Afternoon -February 13, 2025 at 02:03 pm EST - Marketscreener.com
Sector Update: Health Care Stocks Mixed Thursday Afternoon - TradingView
Pliant Therapeutics Moves Forward With Expert Panel Following BEACON-IPF Trial Enrollment Pause - Nasdaq
Sector Update: Health Care -February 13, 2025 at 01:45 pm EST - Marketscreener.com
Stifel maintains Pliant Therapeutics stock buy rating amid study pause - MSN
Pliant stock jumps 28% on bexotegrast study update - MSN
Pliant Therapeutics to Assemble Expert Panel to Review BEACON-IPF Trial Data; Shares Jump - Marketscreener.com
Pliant stock jumps 28% on bexotegrast study update (PLRX:NASDAQ) - Seeking Alpha
Pliant Therapeutics (NASDAQ:PLRX) Reaches New 52-Week LowWhat's Next? - MarketBeat
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis - The Manila Times
Pliant Therapeutics Announces Next Steps Following DSMB - GlobeNewswire
Pliant's IPF Drug Trial Hits Unexpected Hurdle: Expert Panel Called for Urgent Review - StockTitan
What is HC Wainwright’s Estimate for PLRX FY2029 Earnings? - Defense World
Canaccord Genuity Group Reaffirms Hold Rating for Pliant Therapeutics (NASDAQ:PLRX) - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Sets New 1-Year LowTime to Sell? - MarketBeat
Pliant Therapeutics stock hits 52-week low at $2.52 By Investing.com - Investing.com Nigeria
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 8.7%Should You Sell? - MarketBeat
Pliant Therapeutics, Inc. Company Investigated by the Portnoy Law Firm - GlobeNewswire
Pliant pauses mid-stage trial for lung disease therapy - MSN
Canaccord Genuity cuts Pliant to hold on study setback - MSN
Oppenheimer cuts Pliant Therapeutics stock rating amid trial pause - MSN
Pliant Therapeutics (NASDAQ:PLRX) Shares Down 8.7%Should You Sell? - MarketBeat
Pliant stock plunges 61% amid study pause, downgrades - MSN
Citigroup Downgrades Pliant Therapeutics (PLRX) - MSN
Pliant Therapeutics Inc (PLRX) 財務データ
収益
当期純利益
現金流量
EPS
Pliant Therapeutics Inc (PLRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Cummings Keith Lamont | Chief Financial Officer |
Jan 17 '25 |
Sale |
11.20 |
20,148 |
225,680 |
262,608 |
| Hull Hans | Chief Business Officer |
Jan 17 '25 |
Sale |
11.20 |
15,936 |
178,501 |
211,558 |
| Lefebvre Eric | Chief Medical Officer |
Jan 17 '25 |
Sale |
11.20 |
18,478 |
206,974 |
194,574 |
| Cheung Lily | Chief Human Resource Officer |
Jan 17 '25 |
Sale |
11.20 |
3,740 |
41,892 |
24,550 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 17 '25 |
Sale |
11.20 |
13,270 |
148,639 |
80,774 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 22 '25 |
Sale |
10.99 |
10,230 |
112,462 |
70,544 |
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):